USANA Health Sciences, Inc. updated earnings guidance for the year 2023. Fiscal 2023 net sales and diluted EPS guidance updated to $900 to $950 million and $2.65 to $3.30, respectively, from $875 million to $950 million and $2.40 to $3.30.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.44 USD | -0.59% | -3.65% | -15.22% |
May. 07 | DA Davidson Adjusts Price Target on USANA Health Sciences to $46 From $48, Maintains Neutral Rating | MT |
May. 01 | Transcript : USANA Health Sciences, Inc., Q1 2024 Earnings Call, May 01, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.22% | 866M | |
+13.44% | 8.15B | |
-0.41% | 7.26B | |
-3.66% | 5.69B | |
-7.83% | 3.65B | |
-15.68% | 3.37B | |
-11.82% | 1.21B | |
-24.90% | 1.15B | |
+6.46% | 918M | |
-11.82% | 846M |
- Stock Market
- Equities
- USNA Stock
- News USANA Health Sciences, Inc.
- USANA Health Sciences, Inc. Updates Earnings Guidance for the Year 2023